Compare DexCom, Inc. (DXCM) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Keysight Technologies Inc — how do they compare? DexCom, Inc. trades at $84.8 (market cap $31.86B), while Keysight Technologies Inc trades at $380.4 (market cap $63.79B). The key difference: Keysight Technologies Inc is far larger — about 2× DexCom, Inc.'s market cap, and Keysight Technologies Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Keysight Technologies Inc for 56 Days on average.
| DXCM | KEYS | |
|---|---|---|
Market Cap | $31.86B | $63.79B |
Volume | 3,607,070 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $92.34 | $387.90 |
52-Week Low | $54.84 | $159.49 |
Typical Hold Time | 62 Days | 56 Days |
Enterprise Value | $31.32B | $63.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
KEYS trades at $381.49, down 1.65% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue for 2025 reached $5.38 billion with a net income margin of 19.14%, while analyst consensus is strongly bullish with an 81.25% buy rating and a $416.63 price target. Recent news highlights growth in AI infrastructure and 6G technology development.
The outlook for KEYS is positive, driven by accelerating earnings and expanding AI and 6G opportunities, though high valuation multiples and supply chain constraints present risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on tech sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
